+1 202 637 3237
+1 202 637 5910
Associate, Washington, D.C.
Jason Conaty’s practice concentrates on regulatory, enforcement, and transactional matters relevant to the pharmaceutical and biotechnology sectors. Jason counsels clients on matters before the U.S. Food and Drug Administration, including matters arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act. He focuses on intellectual property and clinical development issues; regulatory issues associated with company acquisitions; issues relating to the marketing and promotion of pharmaceuticals; as well as a range of life science- and technology-related litigation matters, including IP litigation and white collar criminal investigations relating to off-label promotion of drugs and medical devices. Jason also advises clients on issues relating to international trade in pharmaceuticals and biotechnology goods.
Jason has a Ph.D. in biochemistry and molecular biology. Prior to joining Hogan & Hartson, Jason was a Fellow of the Leukemia and Lymphoma Society, Fellow in Genetics at Harvard Medical School, and worked at Massachusetts General Hospital. While at law school Jason clerked for the United States Senate Judiciary Committee, in the office of Senator Edward M. Kennedy.
Hogan Lovells Publications
04 October 2012
"FDA denies 5-year exclusivity to “stable esters” and confirms structure-based approach to exclusivity." Pharmaceutical and Biotechnology Alert, Hogan Lovells
11 December 2008
"New IP Law Creates Cabinet-Level IP Enforcement Coordinator." International Trade & Intellectual Property Update, Hogan & Hartson LLP
"Two Draft Guidances Seek to Clarify and Potentially Expand FDA Classification of Device and Drug Products - Hidden Risks and Unexpected Benefits." The Food and Drug Law Institute Update